source
- Marrow Therapeutics raises $173M to develop bone-marrow-targeted gene therapies for blood disordersMarrow Therapeutics announced a $173 million financing round, combining a $53 million Series A led by founder Scion Life Sciences and venBio with a $120 million Series B led by OrbiMed. The compan…
- Marrow Therapeutics raises $173M to develop simpler alternative to gene therapies for sickle cell and beta thalassemiaMarrow Therapeutics, a newly announced biotech startup, has secured $173 million in venture funding to pursue a new treatment for severe blood disorders such as sickle cell disease and beta thalass…BioPharma Dive · 4d agoDealPositive